Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Debt: 2020-2021

  • Whitehawk Therapeutics' Total Debt fell 57.98% to $6.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $6.0 million, marking a year-over-year decrease of 57.98%. This contributed to the annual value of $6.0 million for FY2021, which is 57.98% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Total Debt stood at $6.0 million for Q4 2021, which was up 4.08% from $5.8 million recorded in Q3 2021.
  • In the past 5 years, Whitehawk Therapeutics' Total Debt registered a high of $14.3 million during Q4 2020, and its lowest value of $5.8 million during Q3 2021.
  • Moreover, its 2-year median value for Total Debt was $6.0 million (2021), whereas its average is $8.7 million.
  • Data for Whitehawk Therapeutics' Total Debt shows a maximum YoY slumped of 57.98% (in 2021) over the last 5 years.
  • Whitehawk Therapeutics' Total Debt (Quarterly) stood at $14.3 million in 2020, then slumped by 57.98% to $6.0 million in 2021.
  • Its Total Debt was $6.0 million in Q4 2021, compared to $5.8 million in Q3 2021 and $14.3 million in Q4 2020.